Market
AstraZeneca joins Sweden’s shared supercomputer Computing race intensifies, but no publicly disclosed drug-development results yet

Global drugmakers are moving quickly to secure supercomputers for drug development, but no results have been publicly disclosed yet.
According to TechLifeSci on the 27th (local time), AstraZeneca began operating the shared supercomputer “Sferical One” with Swedish industry partners on the 15th. The system, which includes Ericsson, Saab, SEB and Investor AB, is equipped with 1,152 NVIDIA Blackwell Ultra graphics processing units (GPUs) and reportedly cost more than 1 billion kronor (about 130 billion won) to build.
The race to secure computing capacity in the pharmaceutical industry is already intense. Eli Lilly has operated “LillyPod,” equipped with 1,016 GPUs, since February, while Roche has more than 3,500. Bristol Myers Squibb (BMS) is set to bring in a “Vera Rubin” system in the first quarter of 2027, while Novo Nordisk and Zealand Pharma use Denmark’s “Gefion.”
The problem is results. None of these systems has yet been linked to publicly disclosed drug candidates or utilization figures. Eli Lilly Chief AI Officer Thomas Fuchs said, “The bottleneck is biology.”
More computing capacity means more candidates to validate. Google’s “Deep Review” agent has already reviewed more than 16,000 papers from major machine learning conferences. Some analyses suggest that, in drug development, the bottleneck has shifted to clinical validation.
Meanwhile, AI drug-development companies are actively raising funds. Anthropic has filed for a Nasdaq listing, and according to its registration statement, nine of the 10 Fortune 500 pharmaceutical companies were customers that each spent more than $100,000 in the year ended Sept. 30. Anthropic reported revenue of $16.3 billion in the first half of this year.
Insilico Medicine conducted a $150 million initial public offering (IPO) at $16 per share on the 15th, while Recursion raised an additional $200 million the same day. Isomorphic Labs is reportedly discussing a fundraising round targeting a valuation of $40 billion to $50 billion.
Deals continued as well. AstraZeneca agreed to pay Insitro $40 million upfront and up to about $1.46 billion in milestones. Astellas adopted AI Proteins’ miniprotein platform in a deal worth more than $400 million, including milestones.
China is moving to protect domestic platforms. The Ministry of Commerce proposed banning foreign acquisitions of cell and gene therapy (CGT) and siRNA platforms. Technology exports and contract development and manufacturing organization (CDMO) services would be excluded, and the public comment period runs through the 15th of next month.
OpenAI has expanded its work in biotechnology. About 2,000 GPT-Rosalind agents developed by PerturbAI, OpenAI and The Scripps Research Institute analyzed a whole-brain CRISPR map in mice in 32 minutes, a task that would take people months. OpenAI acquired Orchestra Bio the previous day and integrated it into the Rosalind service.

Biobook Team
biobookmedia@biobook.co.kr
Medtronic to Acquire Contego Medical for $380 Million, Strengthening Carotid Treatment Portfolio

AstraZeneca wins Soliris antitrust lawsuit, with court finding no patent abuse

Alphabet Subsidiary Isomorphic Raises $5 Billion for AI Drug Development

Google Subsidiary Isomorphic Raises Another $5 Billion in Funding in Six Months

Lilly invests $7.9 billion in cancer-targeting technology company in fourth deal in 6 weeks

Samsung Biologics Completes 2.665 Trillion Won Rights Offering; New Shares to List Nov. 30